Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential…
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced positive in vivo data for PNV-5032, as a…